STERIS

STERIS Plc engages in the provision of healthcare and life science product and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capital equipment. The Applied Sterilization Technologies segment is involved in contract sterilization and testing services for medical device and pharmaceutical manufacturers. The Dental segment provides a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. The company was founded in 1985 and is headquartered in Mentor, OH.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

STERIS plc reports 16% revenue growth and anticipates 7-8% growth in fiscal 2024

STERIS plc's Q4 2023 earnings call highlighted strong revenue growth, successful integration of Cantel Medical, and cost synergies exceeding projections. While challenges exist in the AST segment and concerns were raised about labor costs and free cash flow pressure, the outlook for fiscal 2024 indicates potential opportunities for growth.

STERIS plc reports mixed Q2 performance, optimistic about future opportunities

STERIS plc's Q2 2023 earnings call highlighted mixed performance across segments, with strong growth in Healthcare but challenges in the AST and Dental segments. The company remains optimistic about future opportunities, particularly with the Becton, Dickinson deal and updated financial outlook.

STERIS reports Q3 growth, faces margin pressures and supply challenges

STERIS delivered solid revenue growth despite challenges from divestitures and margin pressures.
The company's strategic acquisitions and focus on direct market access position it for future growth.
While facing some headwinds, STERIS remains confident in its long-term growth prospects.
Investors should monitor how the company navigates supply chain strains and capitalizes on bioprocessing demand.

STERIS reports strong Q4 earnings, eyes growth amid challenges

STERIS delivered robust Q4 2023 results with strong revenue growth and net income.
While facing challenges in certain segments, the company remains optimistic about growth opportunities.
Confidence in compliance with EPA regulations and a positive outlook for fiscal 2024.
Strategic capital allocation decisions and cost synergies driving financial performance.

STERIS reports solid Q1 earnings, eyes growth through acquisitions

STERIS' Q1 2024 performance was solid, driven by revenue growth in the healthcare segment. Challenges were seen in the AST and Dental segments due to inventory destocking. The upcoming acquisition and positive growth expectations in Life Sciences present opportunities for future growth.

STERIS reports strong Q2 performance amidst segment challenges

STERIS showcased robust financial performance in Q2 2024, driven by strong organic revenue growth and solid net income. While facing challenges in certain segments, the company remains optimistic about future growth opportunities and is actively managing its debt and cash flow.

STERIS reports strong Q3 earnings, updates 2024 outlook positively

STERIS showcased solid performance in Q3 2024, driven by strong healthcare and life sciences segments. Challenges in AST and Dental segments were noted, with opportunities seen in updated fiscal 2024 outlook and strategic discussions on margin dynamics and expansion.

STERIS reports 7% revenue growth, anticipates margin improvement ahead

STERIS demonstrated solid revenue growth and maintained free cash flow in line with guidance.
While facing margin challenges in certain segments, the company anticipates improvements ahead.
The outlook for organic revenue growth, adjusted EPS, and free cash flow remains positive for the full year.
Overall, STERIS is strategically positioned to capitalize on growth opportunities and address current challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STERIS Plc engages in the provision of healthcare and life science products and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capital equipment. The Applied Sterilization Technologies segment is involved in contract sterilization and testing services for medical device and pharmaceutical manufacturers. The Dental segment offers a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. The company was founded in 1985 and is headquartered in Dublin, Ireland.

STERIS plc (STE) CEO Dan Carestio on Q1 2022 Results - Earnings Call Transcript

Steris (STE) delivered earnings and revenue surprises of 17.33% and 7.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Steris (STE) Q1 Earnings and Revenues Top Estimates

DUBLIN, IRELAND, Aug. 09, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2022 first quarter ended June 30, 2021. Revenue as reported for the quarter increased 45% to $968.4 million compared with $668.9 million in the first quarter of fiscal 2021. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 21% for the first quarter of fiscal 2022 as compared to the first quarter of fiscal 2021, which was negatively impacted by the pandemic.

STERIS Announces Financial Results for Fiscal 2022 First Quarter

Bonanza Creek Energy

Broadridge Financial

Martin Marietta Materials

Tyson Foods

After years of a low interest rate environment, many investors have turned to equities not only for the growth potential but also for solid and dependable dividends that help to provide an income stream.

5 Top Buy-Rated Stocks With Dividend Hikes Expected This Week

Acquisitions of Cantel Medical and Key Surgical are expected to have contributed significantly to STERIS' (STE) first-quarter revenues.

STERIS (STE) to Report Q1 Earnings: What's in the Cards?

DUBLIN, IRELAND , July 27, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2022 first quarter financial results at 10:00 a.m. ET on Tuesday, August 10, 2021. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.

STERIS to Host a Conference Call for Fiscal 2022 First Quarter Financial Results on August 10, 2021

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Steris (STE) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Steris (STE) reported earnings 30 days ago. What's next for the stock?

Steris (STE) Up 5% Since Last Earnings Report: Can It Continue?

STERIS' (STE) acquisition of Cantel Medical will complement and broaden the former's product and service offerings, global reach and customers.

STERIS (STE) Expands Product Suite With New Acquisition

DUBLIN, IRELAND, June 02, 2021 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that it has completed the previously announced acquisition of Cantel Medical, a global provider of infection prevention products and services to endoscopy, dental, dialysis and life sciences Customers.

STERIS Completes the Acquisition of Cantel Medical

Cantel Medical

S&P Global

NEW YORK, May 26, 2021 /PRNewswire/ -- S&P SmallCap 600 constituent Crocs Inc. (NASD:CROX) will replace Cantel Medical Corp. (NYSE:CMD) in the S&P MidCap 400, and Organogenesis Holdings Inc. (NASD: ORGO) will replace Crocs in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, June 2, 2021. STERIS plc (NYSE: STE) is acquiring Cantel Medical in a deal expected to be completed soon pending final closing conditions.

Crocs Set to Join S&P MidCap 400 and Organogenesis to Join S&P SmallCap 600

STERIS plc (STE) CEO Walt Rosebrough on Q4 2021 Results - Earnings Call Transcript

STERIS' (STE) fourth-quarter 2021 revenues improved year over year on robust growth across three segments.

STERIS (STE) Q4 Earnings Fall Shy of Estimates, FY22 View Up

Shares of Steris (NYSE:STE) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 0.61% over the past year to $1.63, which missed the estimate of $1.77.

Recap: Steris Q4 Earnings

DUBLIN, IRELAND, May 18, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2021 fourth quarter ended March 31, 2021. Revenue as reported for the quarter increased 6% to $873.5 million compared with $823.0 million in the fourth quarter of fiscal 2020, with growth in all three segments. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 0.3% for the fourth quarter of fiscal 2021 as compared to constant currency organic revenue results in the fourth quarter of fiscal 2020. For the full fiscal year, revenue as reported increased 3% to $3,107.5 million and constant currency organic revenue was up slightly from the prior year.

STERIS Announces Financial Results for Fiscal 2021 Fourth Quarter and Full Year

STERIS (STE) is likely to have continued to gain from the robust demand of PPE and COVID-19-related products in Q4.

STERIS (STE) to Report Q4 Earnings: What's in the Cards?

DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for election when his term expires on July 29, 2021. In addition, effective May 5, 2021, Paul E. Martin, former Senior Vice President and Chief Information Officer for Baxter International Inc., has been elected to the company's Board of Directors.

STERIS Announces Changes to Board of Directors

DUBLIN, IRELAND, April 27, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2021 fourth quarter and full year financial results at 11:00 a.m. ET on Wednesday, May 19, 2021. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.

STERIS to Host a Conference Call for Fiscal 2021 Fourth Quarter and Full Year Financial Results on May 19, 2021

Align Technology

ICON

PRA Health Sciences

Teladoc

Thermo Fisher Scientific

DENTSPLY SIRONA

While smaller tuck-in acquisitions dominated the M&A space throughout 2020, 2021 is seeing a number of colossal deals.

MedTech M&A Scaling New Heights in 2021 on Rising Investor Wealth

Investors are optimistic about STERIS (STE) owing to strong segmental performance amid the pandemic and huge growth potential in healthcare and pharmaceutical industries.

Here's Why You Should Hold on to STERIS (STE) Stock Now

Steris (STE) Down 6.1% Since Last Earnings Report: Can It Rebound?

NEW ORLEANS, Feb. 9, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Cantel Medical Corp (NYSE: CMD) to STERIS plc (NYSE: STE). Under the terms of the proposed...

CANTEL MEDICAL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cantel Medical Corp - CMD

STERIS plc (STE) CEO Walter Rosebrough on Q3 2021 Results - Earnings Call Transcript

STERIS' (STE) third-quarter fiscal 2021 results reflect strong performance by all three of its reporting segments despite the coronavirus-led economic crisis.

STERIS' (STE) Earnings & Revenues Surpass Estimates in Q3

DUBLIN, IRELAND, Feb. 03, 2021 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that Walt Rosebrough, President and CEO, has announced his intention to step down on July 29, 2021, in conjunction with the company's Annual General Meeting. Mr. Rosebrough will remain as CEO Emeritus and Senior Advisor to STERIS's leadership and Board for the next two years.

News for STERIS Stock (STE)